DS0412 - Innovation médicale, nanotechnologies, médecine régénérative, thérapies et vaccins innovants

Development of in vitro micropatterned neuromuscular junctions – MIMETiC

Submission summary

The neuromuscular junction is a synapse that represents the basic structure by which the activity of spinal motoneurons controls muscle contraction or relaxation during movement. As existing in vitro models do not allow for adequate acquisition of major functional readouts, we propose to develop an innovative reconstruction of mature neuromuscular junctions that can be used to explore electrophysiological features of motoneuron-muscle synaptic transmission and/or to evaluate new drugs developed for the therapy of various neurodegenerative, neuromuscular and muscular diseases. The proposed neuromuscular circuit model consists of co-cultured primary motoneurons-interneurons and skeletal myotubes using a unique micropatterned cell culture substrate. The key objective of our neuromuscular junction model is to create a powerful and versatile platform for pharmacological development by both industrial and fundamental research groups. This will be achieved by i) preserving cellular compartmentalization, ii) keeping functional integrity, and iii) ensuring adaptability to different genetic models. Toward the success of our overall goal, the project brings together the necessary expertise in motoneuron cell biology and electrophysiology, as well as micropatterning technology dedicated to cell based assays with industrial purpose.

Project coordination

Frédérique Scamps (INSERM LANGUEDOC ROUSSILLON)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

INSERM INSERM LANGUEDOC ROUSSILLON
CYTOO

Help of the ANR 228,949 euros
Beginning and duration of the scientific project: September 2015 - 24 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter